Abstract |
The blood concentrations of lidocfaine and its active monodeethylated metabolite, monethylglycinexylidide ( MEGX), were measured in 31 patients who were receiving infusiions of lidocaine intravenously. In 3 patients who were studied intensively, the elimination half-life of MEGX was 120 min, which was similar to the elimination half-life of lidocaine (139 min). An addition 3 patients demonstrated a higher ratio of the concentration in blood of MEGX to lidocaine, and the MEGX may have contributed, in 1 patient, to the central nervous system toxicity that occurred during the infusion. Elevated concentrations of MEGX in blood were associated with congestive heart failure (r equalto 0.5, p equal to 0.004). Our data suggest that the elimination of MEGX may be decreased in patients with depressed cardiac output and sympathomimetic compensation.
|
Authors | H Halkin, P Meffin, K L Melmon, M Rowland |
Journal | Clinical pharmacology and therapeutics
(Clin Pharmacol Ther)
Vol. 17
Issue 6
Pg. 669-76
(Jun 1975)
ISSN: 0009-9236 [Print] United States |
PMID | 1139858
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Chromatography, Gas
- Dealkylation
- Female
- Half-Life
- Heart Failure
(drug therapy, metabolism)
- Humans
- Kinetics
- Lidocaine
(administration & dosage, blood, therapeutic use)
- Male
- Middle Aged
|